Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 2
1991 2
1992 5
1993 4
1995 4
1996 3
1997 3
1998 2
1999 4
2001 1
2002 3
2003 1
2004 2
2007 2
2008 3
2009 4
2010 1
2011 3
2012 4
2013 1
2014 2
2015 1
2016 3
2017 1
2018 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.
Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Jabbour EJ, et al. Leuk Lymphoma. 2014 Jul;55(7):1451-62. doi: 10.3109/10428194.2013.845883. Epub 2013 Nov 12. Leuk Lymphoma. 2014. PMID: 24050507 Free PMC article. Review.
Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing p …
Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular …
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K. Rogers G, et al. Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220. Health Technol Assess. 2012. PMID: 22551803 Free PMC article. Review.
Accelerated and blast crisis: all available data originated from observational single-arm studies and there were considerable and potentially important differences in baseline characteristics which seriously undermined any process for making meaningful comparisons between …
Accelerated and blast crisis: all available data originated from observational single-arm studies and there were considerable and pot …
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Akard L, Kantarjian HM, Nicolini FE, Wetzler M, Lipton JH, Baccarani M, Jean Khoury H, Kurtin S, Li E, Munteanu M, Cortes J. Akard L, et al. Leuk Lymphoma. 2016;57(3):654-65. doi: 10.3109/10428194.2015.1071486. Epub 2015 Oct 5. Leuk Lymphoma. 2016. PMID: 26436949 Free PMC article.
Here, we further examine the patterns of hematologic toxicity observed in clinical trials and describe the approach to management as well as resolution of events. Omacetaxine-related myelosuppression typically occurs more frequently during induction cycles. In general, the …
Here, we further examine the patterns of hematologic toxicity observed in clinical trials and describe the approach to management as …
Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R, Ghedira H, Bellaaj H, Ben Youssef Y, Menif S, Manai Z, Bedoui M, Lakhal A, M'Sadek F, Elloumi M, Khélif A, Ben Romdhane N, Laatiri MA, Ben Othmen T, Meddeb B. Ben Lakhal R, et al. Ann Hematol. 2018 Apr;97(4):597-604. doi: 10.1007/s00277-017-3224-2. Epub 2018 Jan 6. Ann Hematol. 2018. PMID: 29305630
The following prognostic factors were analyzed for their impact on the European leukemia net (ELN) response, OS, EFS, and PFS at 5 years: age, sex, leukocyte count, Sokal score, European Treatment and Outcome Study (EUTOS) score, CML phase, time to starting IM, and …
The following prognostic factors were analyzed for their impact on the European leukemia net (ELN) response, OS, EFS, and PFS at 5 years: ag …
Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia.
Liu JH, Yen CC, Lin YC, Gau JP, Yang MH, Chao TC, Hsiao LT, Wang WS, Tsai YC, Chen PM. Liu JH, et al. Leuk Lymphoma. 2004 Dec;45(12):2419-25. doi: 10.1080/10428190400003317. Leuk Lymphoma. 2004. PMID: 15621754
These results suggest that the expression level of cyclin D1 RNA in bone marrow cells is predictive of the phase evolution in CML and may be helpful in treatment decision-making....
These results suggest that the expression level of cyclin D1 RNA in bone marrow cells is predictive of the phase evolution in CML and …
Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling.
Su W, Meng F, Huang L, Zheng M, Liu W, Sun H. Su W, et al. Exp Hematol. 2012 May;40(5):418-27. doi: 10.1016/j.exphem.2012.01.003. Epub 2012 Jan 10. Exp Hematol. 2012. PMID: 22240607 Free article.
Differential activation of Shh signaling was found in about 50% CML chronic phase samples, about 70% of CML accelerated phase samples, and >80% CML blast crisis phase samples. Deregulated activation of Shh signaling was observed in CD34(+) and c-kit(+) leukemia progenit …
Differential activation of Shh signaling was found in about 50% CML chronic phase samples, about 70% of CML accelerated phase samples, and & …
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Kantarjian HM, et al. Clin Cancer Res. 2002 Jul;8(7):2167-76. Clin Cancer Res. 2002. PMID: 12114417 Clinical Trial.
In multivariate analyses, a diagnosis-to-treatment interval of 3 years or more, splenomegaly, and peripheral blasts predicted poor major cytogenetic response; age >60 years, marrow basophilia, and clonal evolution predicted poor survival. ...
In multivariate analyses, a diagnosis-to-treatment interval of 3 years or more, splenomegaly, and peripheral blasts predicted poor ma …
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ, Alberts DS, Arlin Z, Ahmed T, Mittelman A, Baskind P, Peng YM, Baier M, Plezia P. Feldman EJ, et al. J Clin Oncol. 1993 Oct;11(10):2002-9. doi: 10.1200/JCO.1993.11.10.2002. J Clin Oncol. 1993. PMID: 8410125 Clinical Trial.
RESULTS: Severe, but reversible hyperbilirubinemia (> three times normal) was considered the dose-limiting toxicity, and was observed in 25% of all patients and in 35% of those who received 70 to 80 mg/m2 of mitoxantrone. ...
RESULTS: Severe, but reversible hyperbilirubinemia (> three times normal) was considered the dose-limiting toxicity, and was observed …
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM. le Coutre PD, et al. Leukemia. 2012 Jun;26(6):1189-94. doi: 10.1038/leu.2011.323. Epub 2011 Nov 11. Leukemia. 2012. PMID: 22076466 Clinical Trial.
The estimated overall and progression-free survival rates at 24 months were 70% and 33%, respectively. Grade 3/4 neutropenia and thrombocytopenia were each observed in 42% of patients. Non-hematologic adverse events were mostly mild to moderate; the safety profile of nilot …
The estimated overall and progression-free survival rates at 24 months were 70% and 33%, respectively. Grade 3/4 neutropenia and thrombocyto …
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A. Nicolini FE, et al. Leuk Lymphoma. 2012 May;53(5):907-14. doi: 10.3109/10428194.2011.627480. Epub 2011 Dec 5. Leuk Lymphoma. 2012. PMID: 22023530 Clinical Trial.
While an analysis of efficacy was not the primary objective of this study, significant hematologic and cytogenetic responses were observed. These results support the safety and efficacy of nilotinib in patients with advanced CML in AP and BC....
While an analysis of efficacy was not the primary objective of this study, significant hematologic and cytogenetic responses were observe …
58 results